Tamoxifen and Breast Cancer

Presents a balanced and accessible discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. The book also traces the history and evolution of tamoxifen as a treatment for breast cancer.

---

Tamoxifen is one of the most widely prescribed drugs used to prevent the recurrence of breast cancer. A non-steroidal antiestrogen, it has been successful in treating postmenopausal women at nearly all stages of breast cancer. Despite its popularity, however, disturbing questions remain about the use of this drug. How effective is tamoxifen in treating patients who have hormone-insensitive breast tumours or who have not yet reached menopause? What are the potential risks in taking tamoxifen, and do they ever outweigh its benefits? Should tamoxifen be administered as a prophylactic drug for healthy premenopausal women who are at high risk of developing breast cancer? In this book, two leading scientific investigators present a balanced and accessible discussion of the diagnosis of breast cancer and the risks, benefits, and limitations of treatment alterntives, particularly tamoxifen. Michael W. DeGregorio and Valerie Wiebe discuss the history and evolution of tamoxifen as a treatment for breast cancer, explaining how it works, what its side effects are, and why tamoxifen treatment is unsuccessful for some women.
They present the controversies surrounding the National Cancer Institute's study of tamoxifen as a preventive for breast cancer, describing the hopes of the proponents of the study and the fears of its detractors (potential risks to womcn in the study include thrombosis, uterine cancer, and even breast cancer itself). The book is also an aid to women faced with decisions about treatment or prevention of breast cancer.